Literature DB >> 3106490

Human T cell clones use a CD3-associated surface antigen recognition structure to exhibit both NK-like and allogeneic cytotoxic reactivity.

V David, J F Bourge, P Guglielmi, D Mathieu-Mahul, L Degos, A Bensussan.   

Abstract

In the present study, we developed human non-MHC-restricted CTL clones from human peripheral blood mononuclear cells activated in vitro with recombinant IL 2 and subsequently expended with PHA. The CD3/Ti+ clones were selected for their ability to exhibit non-MHC-restricted CTL reactivity by killing various tumor cell lines in culture, including the line K562 which does not express MHC antigens. We report that, at least for some of the NK-like T cell clones, it is possible to establish an allo-CTL activity, and that the CD3-associated surface antigen recognition structure might be involved in both reactivities.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3106490

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


  10 in total

1.  T-cell receptor gene rearrangement and expression in human natural killer cells: natural killer activity is not dependent on the rearrangement and expression of T-cell receptor alpha, beta, or gamma genes.

Authors:  J M Leiden; K M Gottesdiener; T Quertermous; L Coury; R A Bray; L Gottschalk; H Gebel; J G Seidman; J L Strominger; A L Landay
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

2.  BY55 monoclonal antibody delineates within human cord blood and bone marrow lymphocytes distinct cell subsets mediating cytotoxic activity.

Authors:  A Bensussan; E Gluckman; S el Marsafy; V Schiavon; I G Mansur; J Dausset; L Boumsell; E Carosella
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

3.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.

Authors:  D L Barnd; M S Lan; R S Metzgar; O J Finn
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors.

Authors:  L Le Cleach; S Delaire; L Boumsell; M Bagot; I Bourgault-Villada; A Bensussan; J C Roujeau
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

5.  Detection of membrane-bound HLA-G translated products with a specific monoclonal antibody.

Authors:  A Bensussan; I G Mansur; V Mallet; A M Rodriguez; M Girr; E H Weiss; G Brem; L Boumsell; E Gluckman; J Dausset
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

6.  Studies on cytotoxicity generated in human mixed lymphocyte culture. IV. Interleukin 2 alone or from mixed lymphocyte culture yields natural killer-like cytotoxic cells distinct from allospecific cytotoxic T lymphocytes.

Authors:  H Shau; J D Gray; S H Golub
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Studies of lymphokine-activated killer (LAK) cells. I. Evidence using novel monoclonal antibodies that most human LAK precursor cells share a common surface marker.

Authors:  D G Morris; H F Pross
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

Review 8.  Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms.

Authors:  Ro-Lan Dao; Shih-Chi Su; Wen-Hung Chung
Journal:  Asia Pac Allergy       Date:  2015-04-29

9.  Identification of a human T cell clone with the cytotoxic T lymphocyte and natural killer-like cytotoxic function against autologous mammary carcinoma and K562 line.

Authors:  T Sato; M Okubo; Y Wada; N Sato; K Kikuchi
Journal:  Jpn J Cancer Res       Date:  1989-07

10.  A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity.

Authors:  H Maïza; G Leca; I G Mansur; V Schiavon; L Boumsell; A Bensussan
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.